Treatment of wet age-related macular degeneration : Now and future / 中华实验眼科杂志
Chinese Journal of Experimental Ophthalmology
;
(12): 63-68, 2019.
Article
in Chinese
| WPRIM
| ID: wpr-733644
ABSTRACT
Wet age-related macular degeneration (AMD),which is the leading cause of visual impairment in elderly people,significantly affects quality of life of millions worldwide.Currently,anti-VEGF is the first-line therapy for wAMD,bringing encouraging results in improving the vision.However,not all of the patients will response to this therapy,moreover,anti-VEGF may be associated with several issues,such as multiple injections,systemic adverse effects,delay or lack of response.With a deep understanding of the mechanism of wAMD,there are rapid developments of new approaches to more effective therapy.Ophthalmologists should pay attention to the advantages and disadvantages of these anti-VEGF drugs as well as the current advances of anti-VEGF drugs in order to provide better treating strategies for wAMD patients better.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Experimental Ophthalmology
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS